Cara Therapeutic
Cara Therapeutics, Inc. operates as a biopharmaceutical company that focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelike… Read more
Cara Therapeutic (CARA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: 0.880x
Based on the latest financial reports, Cara Therapeutic (CARA) has a cash flow conversion efficiency ratio of 0.880x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.04 Million) by net assets ($-4.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cara Therapeutic - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Cara Therapeutic's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cara Therapeutic Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cara Therapeutic ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mooncor Oil & Gas Corp
V:MOO
|
0.128x |
|
KESM Industries Bhd
KLSE:9334
|
0.032x |
|
NanoCMS Co. Ltd.
KQ:247660
|
0.046x |
|
Suraj Limited
NSE:SURAJLTD
|
N/A |
|
Wijaya Karya Bangunan Gedung Tbk PT
JK:WEGE
|
-0.007x |
|
Jufan Industrial Co., Ltd.
TWO:4584
|
-0.004x |
|
Heart Test Laboratories Inc. Common Stock
NASDAQ:HSCS
|
-558.107x |
|
Cambium Bio Ltd
AU:CMB
|
-1.444x |
Annual Cash Flow Conversion Efficiency for Cara Therapeutic (2011–2024)
The table below shows the annual cash flow conversion efficiency of Cara Therapeutic from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-4.59 Million | $-60.92 Million | 13.263x | +922.26% |
| 2023-12-31 | $57.09 Million | $-92.08 Million | -1.613x | -225.30% |
| 2022-12-31 | $158.78 Million | $-78.73 Million | -0.496x | -87.75% |
| 2021-12-31 | $227.52 Million | $-60.09 Million | -0.264x | -1098.46% |
| 2020-12-31 | $249.00 Million | $-5.49 Million | -0.022x | +96.23% |
| 2019-12-31 | $186.71 Million | $-109.22 Million | -0.585x | -250.53% |
| 2018-12-31 | $133.63 Million | $-22.30 Million | -0.167x | +73.59% |
| 2017-12-31 | $86.78 Million | $-54.83 Million | -0.632x | +32.36% |
| 2016-12-31 | $50.73 Million | $-47.38 Million | -0.934x | -356.84% |
| 2015-12-31 | $105.04 Million | $-21.48 Million | -0.204x | +40.12% |
| 2014-12-31 | $51.66 Million | $-17.64 Million | -0.341x | -238.95% |
| 2013-12-31 | $11.51 Million | $2.83 Million | 0.246x | +109.94% |
| 2012-12-31 | $2.44 Million | $-6.03 Million | -2.473x | -120.51% |
| 2011-12-31 | $6.10 Million | $-6.84 Million | -1.121x | -- |